Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC decreased its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 23.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,934 shares of the company’s stock after selling 1,525 shares during the period. Hsbc Holdings PLC’s holdings in Tarsus Pharmaceuticals were worth $273,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of TARS. Barclays PLC boosted its position in shares of Tarsus Pharmaceuticals by 345.9% during the 3rd quarter. Barclays PLC now owns 98,663 shares of the company’s stock valued at $3,246,000 after purchasing an additional 76,538 shares in the last quarter. JPMorgan Chase & Co. grew its position in Tarsus Pharmaceuticals by 2,088.8% in the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock worth $14,477,000 after buying an additional 420,057 shares during the last quarter. Harbor Capital Advisors Inc. increased its holdings in shares of Tarsus Pharmaceuticals by 22.1% in the fourth quarter. Harbor Capital Advisors Inc. now owns 22,113 shares of the company’s stock valued at $1,224,000 after buying an additional 4,008 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Tarsus Pharmaceuticals by 0.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,146,812 shares of the company’s stock valued at $63,499,000 after acquiring an additional 5,565 shares during the last quarter. Finally, R Squared Ltd bought a new stake in shares of Tarsus Pharmaceuticals during the 4th quarter worth $53,000. Institutional investors own 90.01% of the company’s stock.

Wall Street Analyst Weigh In

TARS has been the subject of several analyst reports. Barclays reduced their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Jefferies Financial Group lifted their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. HC Wainwright restated a “buy” rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Oppenheimer boosted their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Finally, Guggenheim increased their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a “buy” rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $66.33.

Tarsus Pharmaceuticals Stock Down 4.8 %

TARS stock opened at $44.87 on Friday. The company has a 50 day moving average of $48.26 and a two-hundred day moving average of $49.07. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a 12-month low of $20.08 and a 12-month high of $57.28. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -11.78 and a beta of 0.94.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The firm had revenue of $78.34 million during the quarter, compared to analysts’ expectations of $72.50 million. On average, equities analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Insider Activity at Tarsus Pharmaceuticals

In related news, General Counsel Bryan Wahl sold 3,341 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the completion of the sale, the general counsel now directly owns 58,057 shares in the company, valued at approximately $2,687,458.53. This represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Bobak R. Azamian sold 7,131 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $330,093.99. Following the transaction, the chief executive officer now owns 70,720 shares in the company, valued at approximately $3,273,628.80. This trade represents a 9.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,542 shares of company stock valued at $1,581,173. 8.25% of the stock is owned by corporate insiders.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.